At the recently concluded American Society of Clinical Oncology meeting, Gilead Sciences, Inc. and Arcus Biosciences, Inc. joined the ranks of firms developing combinations of PD-1 and PD-L1 inhibitors with monoclonal antibodies targeting TIGIT that have not yet lived up to everyone’s expectations in lung cancer.
Lung cancer specialists, meanwhile, hope to see more in the way of biomarkers that might lead to better efficacy for
KEY TAKEAWAYS
-
Updated data at ASCO from the Phase II ARC-7 trial of Gilead Arcus's PD-1 inhibitor zimberelimab and TIGIT inhibitor domvanalimab were positive, but PFS was lower than expected.
-
The data leave open questions about the role of checkpoint inhibitor combinations and skepticism about TIGIT.
-
Clinicians interviewed by Scrip note there was benefit in some patients, and biomarkers such as PD-L1 expression could help identify an appropriate patient population
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?